Source: Annual Congress 2007 - New treatments for asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Zeldin, M. Massanari, M. Blogg, P. Jimenez, G. Geba (East Hanover, NJ, United States Of America; Horsham, West Sussex, United Kingdom). Treatment of moderate-severe asthma with omalizumab is associated with a decrease in peripheral blood eosinophils. Eur Respir J 2007; 30: Suppl. 51, 2132

Member's Comments

No comment yet.

Related content which might interest you: Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study Source: Eur Respir J, 51 (5) 1702523; 10.1183/13993003.02523-2017 Year: 2018 FENO and blood eosinophil count as surrogate barkers of eosinophilic airway inflammation in patients with severe asthma Source: Annual Congress 2010 - Induced sputum in relation: a fresh look on phenotyping and monitoring Year: 2010 Increase in systemic IL-5 is associated with mepolizumab treatment failure in patients with severe asthma Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018 Mast cells are associated with exacerbations and eosinophilia in children with severe asthma Source: Eur Respir J 2016; 48: 1320-1328 Year: 2016 Association between blood eosinophil count and exacerbation risk in patients with asthma receiving medium- or high-dosage inhaled corticosteroids Source: International Congress 2017 – Biomarker-based asthma control Year: 2017 In vitro responses of peripheral blood mononuclear cells in severe asthma patient treated with Mepolizumab Source: Virtual Congress 2020 – Novel immunopathological mechanisms of lung disease: knowledge from translational studies Year: 2020 Mepolizumab does not alter blood basophil count in severe asthma Source: International Congress 2019 – COPD, asthma and rhinitis: from cellular mechanisms to patients’ clinical responses Year: 2019 Associations of blood cytokines and eosinophils in severe asthma Source: International Congress 2017 – Clinical points to ponder in asthma Year: 2017 Stability of blood eosinophils over time in patients with asthma Source: Virtual Congress 2021 – Biomarkers to phenotype asthma: prediction of exacerbations Year: 2021 T-regulatory cells blood content in patients with asthma exacerbation Source: Annual Congress 2011 - T-cell subsets Year: 2011 Clinical analysis of acute exacerbation of COPD cases with increased eosinophilic granulocytes in peripheral blood Source: International Congress 2019 – Airway disease-associated exacerbations Year: 2019 Peripheral neutrophil stiffness is increased in COPD severe exacerbations Source: Annual Congress 2012 - COPD monitoring in stable disease and during exacerbation Year: 2012 Treatment of COPD exacerbations is able to influence the mononuclear cells level of the peripheral blood Source: Annual Congress 2008 - Basic science in asthma and COPD II Year: 2008 Standard therapy increases the sensitivity of peripheral blood lymphocytes to glucocorticoids in cystic fibrosis but not in severe asthma Source: Annual Congress 2011 - Experimental modulation of airway inflammation Year: 2011 Airway eosinophilia is not related to clinical and functional findings in a large group of severe refractory asthmatics Source: Annual Congress 2006 - Monitoring airway inflammation – exhaled markers vs induced sputum Year: 2006 Late Breaking Abstract - Benralizumab treatment strongly reduces blood basophils in patients with severe eosinophilic asthma Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 Late Breaking Abstract - The blood eosinophils count as a predictor of the response for omalizumab (OMA) in patients suffering from severe allergic asthma Source: International Congress 2019 – Blood eosinophils and more in airway diseases Year: 2019 Heterogeneous response of airway eosinophilia to biologics in severe asthma patients Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Sputum analysis reveals eosinophilic inflammation in difficult-to-control asthma patients with low blood eosinophils and FENO. Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020